Selinexor, bortezomib, dexamethasone cost effective in previously treated multiple myeloma
Condition: Multiple Myeloma Interventions: Drug: REGN5458; Drug: Daratumumab; Drug: Carfilzomib; Drug: Lenalidomide; Drug: Bortezomib; Drug: Dexamethasone Sponsor: Regeneron Pharmaceuticals Not yet recruiting
We present real word retrospective analysis of 108 cases analyzing clinical features and therapeutic modes. We compare our results with the available literature. This is the first description with such wide use of proteasome inhibitors in first line treatment. POEMS (Polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes) syndrome is a rare and challenging plasma cell disorder, both in the diagnostic and therapeutic management of the disease. Currently, the literature on POEMS is sparse with most evidence being case reports and small case studies. We present a retrospective real world experience of 108 patie...
Contributor : Rongfang WeiSeries Type : OtherOrganism : Homo sapiensDetection of protein translation status at the gene level. Ribo-seq experiment of human multiple myeloma cells including NAT10 overexpression and controls were conducted.
Contributor : Rongfang WeiSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Homo sapiensTo identify the ac4C acetylation in the human multiple meloma cells .acRIP-seq and RNA-seq experiments of human multiple myeloma cells including NAT10 overexpression and controls were conducted.
Multiple myeloma is a heterogeneous plasma cell malignancy that remains incurable because of the tendency of relapse for most patients. Survival outcomes may vary widely due to patient and disease variables; therefore, it is necessary to establish a more accurate prognostic model to improve prognostic precision and guide clinical therapy. Here, we developed a risk score model based on myeloma gene expression profiles from three independent datasets: GSE6477, GSE13591, and GSE24080. In this model, highly survival-associated five genes, including EPAS1, ERC2, PRC1, CSGALNACT1, and CCND1, are selected by using the least absol...
European Journal of Human Genetics, Published online: 30 November 2021; doi:10.1038/s41431-021-00986-8A polygenic risk score for multiple myeloma risk prediction